Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Chad Stevens traveled from Idaho to Omaha's Nebraska Medical Center, where he became the hospital's first patient to receive ...

Plainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

Over one-third of hemophilia patients experience bleeding episodes and joint damage despite prophylactic therapies, indicating a need for more effective treatments. Data from the Adelphi ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Columnist Jennifer Lynne knows that finding a sense of community can be challenging, but she's also learned it's worth it.

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Stevens, 63, suffers from hemophilia B, a bleeding disorder caused by a genetic mutation that affects production of a type of protein known as factor 9. Over the years, bleeds have damaged his joints.